Addiction, comorbidity and new psychoactive substances thumbnail
Pause
Mute
Subtitles not available
Playback speed
0.25
0.5
0.75
1
1.25
1.5
1.75
2
Full screen

Addiction, comorbidity and new psychoactive substances

Published on Sep 07, 20151743 Views

Patients with substance use and related addictive disorders have higher prevalence of co-morbid mental health disorders compared to general population; and vice versa, the prevalence of substance use

Related categories

Chapter list

Addiction, comorbidity and new psychoactive substances (nps)00:00
Introduction - 100:02
Introduction - 200:39
Introduction - 301:19
Lifetime prevalence02:53
Demographic, clinical and historical correlates of substance abuse03:40
Etiology04:04
Common factor models04:23
Slovenian study04:40
Results05:19
Number of patients with comorbidity (N=228)05:24
Number of patients by suicide attempt or suicide in family (N=222)05:25
Number of patients by substance use in family (N=223)05:37
Number of patients by criminal proceedings (N=227)05:44
Number of patients by senteced to prison (N=223)05:49
Number of patients by victimisation (N=227)05:54
Number of patients by history of overdose (N=228)06:06
Number of patients by history of suicide attempt (N=227)06:20
Number of patients by number of suicide attempts (N=62)06:25
Number of patients by time of suicide attempt (N=59)06:36
Study results06:43
Number of patients by history of overdose (p=0,013)06:56
Treatment of patients with comorbidity - 107:04
Treatment of patients with comorbidity - 208:04
Comorbidity - treatment approaches08:38
Number of patients addmited to czopd in 201309:21
Comorbid psychiatric disorders09:41
New psychoactive substances (nps) - terminology10:20
Nps definition11:13
Nps12:06
Number of psychoactive substances12:26
Internet availability12:37
Number of internet nps12:56
Advantages of nps13:19
Nps - categories14:59
Categories (Madras,2012)15:13
Specific groups of users16:01
Nps and comorbidity18:23
Number of deaths19:07
Synthetic cannabinoides19:41
The challenge20:33
Synthetic cannabinoides – pharmacology20:44
Cannabis and psychosis21:54
Variations in a gene22:17
Synthetic cannabinoides – psychiatric side effects22:31
Letters to the editor23:25
Peripheral effects23:51
Summary of features of acute SC toxicity24:08
Stimulans neurobiology24:20
Synthetic stimulans24:56
Synthetic cathinones25:15
Chemical structures of cathinone25:54
Synthetic cathinones - effects25:57
Synthetic cathinones adverse effects26:34
Some common unwanted effects of mephedrone26:58
Features of acute mephedrone toxicity27:07
Synthetic cathinones’ psychiatric adverse effects - 127:24
Electroconvulsive therapy28:06
Synthetic cathinones’ psychiatric adverse effects - 128:11
Withdrawal symptoms - stimulants28:44
Nps in Slovenia29:13
A case report: bath salt induced psychosis - 130:21
A case report: bath salt induced psychosis - 231:16
Pentedrone32:10
Thank you for attention33:08